Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ENTX 1.71 0.00(0.00%)
Will ENTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Other News for ENTX
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024
Entera Bio Receives Strong Buy Rating Amid Anticipated FDA Ruling and Pipeline Progress
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Clarifies Non-Binding Information Disclosure